Quartz·2 min read·medium
GSK is slashing costs by $2.5 billion to fast-track its drug pipeline
✦AI Summary
GSK is implementing a $2.5 billion cost-cutting initiative to accelerate its drug development pipeline. The company plans to initiate over 20 phase III clinical trials by 2026 following strong second-quarter profit results.
The British drugmaker beat second-quarter profit expectations and now expects to start 20 or more phase III trials in 2026
businesssciencehealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in